Characteristics of patients with incident critical bleeds (n = 6)
| Age (y) . | Sex . | ITP stage . | Initial platelets count (×109/L) . | ASA, NSAID, or anticoagulant at presentation or during visit . | Comorbidities . | Treatment history . | Noncritical concurrent sites of bleeding . | Sites of critical bleeding . | Time between initial presentation and critical bleed (d) . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|
| 85 | Female | Chronic | 1 | Warfarin, ASA, and LMWH | CHF | Prednisone/prednisolone and other ITP treatment | Oral, epistaxis, gastrointestinal, urinary, skin, and purpura | ICH | 21 | Death∗ |
| 49 | Female | Chronic | 5 | None | Pulmonary sarcoidosis, CVID, and autoimmune hemolytic anemia | Dexamethasone, romiplostim, platelet transfusion, splenectomy, and other ITP treatment | Oral, gastrointestinal, skin, and coffee ground emesis | ICH | 2 | Alive |
| 50 | Female | Newly diagnosed | <20 | None | None | None | Skin | ICH | 2 | Alive |
| 74 | Male | Persistent | 19 | None | MI, diabetes, and CAD | IV immunoglobulin, prednisone/prednisolone, splenectomy | None | ICH | 1 | Death† |
| 37 | Female | Chronic | 16 | Other Anticoagulant | CVA or TIA and venous sinus thrombosis | IV immunoglobulin, prednisone/prednisolone, dexamethasone, methylprednisolone, eltrombopag, and splenectomy | Oral and skin | ICH with respiratory compromise | 1 | Alive |
| 3 | Male | Newly diagnosed | <20 | None | None | None | Skin | Epistaxis with hemodynamic instability | 1 | Alive |
| Age (y) . | Sex . | ITP stage . | Initial platelets count (×109/L) . | ASA, NSAID, or anticoagulant at presentation or during visit . | Comorbidities . | Treatment history . | Noncritical concurrent sites of bleeding . | Sites of critical bleeding . | Time between initial presentation and critical bleed (d) . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|
| 85 | Female | Chronic | 1 | Warfarin, ASA, and LMWH | CHF | Prednisone/prednisolone and other ITP treatment | Oral, epistaxis, gastrointestinal, urinary, skin, and purpura | ICH | 21 | Death∗ |
| 49 | Female | Chronic | 5 | None | Pulmonary sarcoidosis, CVID, and autoimmune hemolytic anemia | Dexamethasone, romiplostim, platelet transfusion, splenectomy, and other ITP treatment | Oral, gastrointestinal, skin, and coffee ground emesis | ICH | 2 | Alive |
| 50 | Female | Newly diagnosed | <20 | None | None | None | Skin | ICH | 2 | Alive |
| 74 | Male | Persistent | 19 | None | MI, diabetes, and CAD | IV immunoglobulin, prednisone/prednisolone, splenectomy | None | ICH | 1 | Death† |
| 37 | Female | Chronic | 16 | Other Anticoagulant | CVA or TIA and venous sinus thrombosis | IV immunoglobulin, prednisone/prednisolone, dexamethasone, methylprednisolone, eltrombopag, and splenectomy | Oral and skin | ICH with respiratory compromise | 1 | Alive |
| 3 | Male | Newly diagnosed | <20 | None | None | None | Skin | Epistaxis with hemodynamic instability | 1 | Alive |
ITP stage: newly diagnosed ITP (<3 months); persistent ITP (3-12 months); and chronic ITP (>12 months).
ASA, aspirin; CAD, coronary artery disease; CHF, congestive heart failure; CVA, cerebrovascular accident; CVID, common variable immunodeficiency; LMWH, low molecular weight heparin; MI, myocardial infarction; NSAID, nonsteroidal anti-inflammatory drug; TIA, transient ischemic attack.
Cause of death by CHF.
Cause of death by intracranial bleed.